Congressional Hearing Intensifies Scrutiny on Pharmacy Benefit Managers

Lawmakers from both parties challenge PBMs on practices that allegedly inflate drug prices and limit patient options.

House Oversight Committee criticizes PBMs for steering patients toward higher-priced medications.
Executives from major PBMs defend their role, blaming drug manufacturers for high costs.
New bipartisan bill aims to increase transparency and reform PBM practices.
Report alleges PBMs are moving operations overseas to avoid regulatory scrutiny.
FTC plans to sue major PBMs over their business practices.